Search Results

51 - 60 of 82 items :

  • pharmacokinetics x
  • Life Sciences x
Clear All
Consensus. Chinese Consensus on Combination Therapy of Chronic Hepatitis B
Professional Staff Committee of Combination Therapy of Chronic Hepatitis B

AS, Heathcote J. Effect of alpha-interferon treatment in patients with hepatitis B e antigen-positive chronic hepatitis B. A meta-analysis. Ann Intern Med 1993;119:312-323. 25 Harris JM, Martin NE, Modi M. Pegylation: a novel process for modifying pharmacokinetics. Clin Pharmacokinet 2001;40:539-551. 26 Lau GK, Piratvisuth T, Luo KX, Marcellin P, Thongsawat S, Cooksley G, et al. Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B. N Engl J Med 2005;352:2682-2695. 27 Sarin SK

Open access
Dehorning of Calves – Methods of Pain and Stress Alleviation – A Review

/12/1991. Council Directive 97/2/ECof 20 January 1997 amending Directive 91/629/EEClaying down minimum standards for the protection of calves. Official Journal L 025, 28/01/1997. Delatour P., Foot R., Foster A.P., Bagott D., Lees P. (1996). Pharmacodynamics and chiral pharmacokinetics of carprofen in calves. Brit. Vet. J., 152: 183-198. Doherty T.J., Kattesh H.G., Adcock R.J., Welborn M.G., Saxton A.M., Morrow J.L., Dailey J.W. (2007). Effects ofaconcentrated lidocaine solution on the acute phase stress response to dehorning in dairy calves. J

Open access
The Effect of Administration of Silver Nanoparticles on the Immune Status of Chickens

extracellular nanoparticle clearance by human immune cells. Nano Lett., 10: 59-63. Bomski H. (1995). Biernacki’s reaction (in Polish). In: Basic hematology laboratory analyses, Bomski H. (ed.). National Institute of Medical Publications, Warsaw, pp. 161-168. Cho W.S., Cho M., Jeong J., Choi M., Cho H.Y., Han B.S., Kim S.H., Kim H.O., Lim Y.T., Chung B.H., Jeon J. (2009). Acute toxicity and pharmacokinetics of 13 nm-sized PEG-coated gold nanoparticles. Tox. Appl. Pharmacol., 236: 16-24. Chuammitri P., Ostojić J., Andreasen C

Open access
Role of Mesenchymal Stem Cells—Derived Exosomes in Osteoarthritis Treatment

secretome and exosomes. Biochemie , 95, 2229e2234. 22. Meirelles, L. S., Fontes, A. M., Covas, D. T., Caplan, A. I., 2009: Mechanisms involved in the therapeutic properties of mesenchymal stem cells. Cytokine Growth Factor Rev. , 20, 419—427. 23. Morishita, M., Takahashi, Y., Nishikawa, M., Takakura, Y., 2017: Pharmacokinetics of exosomes – an important factor for elucidating the biological roles of exosomes and for the development of exosome-based therapeutics. J. Pharm. Sci. , 106, 2265—2269. 24. Pan, B. T., Johnstone, R. M., 1983: Fate of the

Open access
Health-promoting properties of compounds derived from Capsicum sp. A review

450 isozyme activities. Drug Metab Dispos 2016; pii: dmd.116.073213. doi: 86. Zhai XJ, Chen JG, Liu JM, Shi F, Lu YN. Food-drug interactions: effect of capsaicin on the pharmacokinetics of simvastatin and its active metabolite in rats. Food Chem Toxicol 2013; 53:168-173. doi: 87. Zhu C, Zhai X, Chen F, Wang N, Zhang X, Lu Y. Capsaicin induces metabolism of simvasatin in rat: involvement of upregulating expression of Ugt1a1. Pharmazie 2016; 71

Open access
Immune response of mice to Echinococcus multilocularis infection after therapy with amphotericin B colloidal dispersion

. Vet. J., 165: 266–275 [9] Christiansen, K. J., Bernard, E. M., Gold, J. W. M., Armstrong, D. (1985): Distribution and activity of amphotericin B in humans. J. Infect. Dis., 152: 1037–1043 [10] Clements, J. S. Jr., Peacock, J. E. Jr. (1990): Amphotericin B revisited: reassessment of toxicity. Amer. J. Med., 88: 22–27 [11] Clemons, K. V., Sobel, R. A., Williams, P. L., Stevens, D. A. (2001): Comparative toxicities and pharmacokinetics of

Open access
Psychoactive plants used in designer drugs as a threat to public health

, Valle M, Urbano G, yritia M, Morte A, Barbanoj MJ. Human pharmacology of ayahuasca: subjective and cardiovascular effects, monoamine metabolite excretion, and pharmacokinetics. J Pharmacol Exp Ther 2003; 306(1):73-83. 76. Osmond H. Ololiuqui: the ancient Aztec narcotic remarks on the effects of Rivea corymbosa (Ololiuqui). J Ment Sci 1955; 101 (424):526-537. 77. Piekoszewski W, Florek E. Dopalacze. Przegl Lek 2009; 66(10):861-865. 78. Rech MA, Donahey E, Cappiello Dziedzic JM, Oh L, Greenhalgh E. New drugs of abuse

Open access
Redox Status, Hematological Parameters as Well Liver and Kidney Function Indicators in Blood of Chickens Receiving Gold Nanoparticles

). Acute toxicity and pharmacokinetics of 13 nm-sized PEG-coated gold nanoparticles. Tox. Appl. Pharmacol., 236: 16–24. Connor E.E., Mwamuka J., Gole A., Murphy C.J., Wyatt M.D. (2005). Gold nanoparticles are taken up by human cells but do not cause acute cytotoxicity. Small, 1: 325–327. Dobrovolskaia M.A., Patri A.K., Zheng J., Flogston J.D., Ayub N., Aggarwal P. (2009). Interaction of colloidal gold nanoparticles with human blood: effects on particle size and analysis of plasma protein binding profiles. Nanomedicine, 5: 106–117. Dykman L., Khlebtsov N

Open access
Study of troponin, creatine kinase biomarkers, and histopathological lesions in experimental Nerium oleander toxicity in rats and mice

20 Narayane V.S., Pawakar A.P., Souza A.A., Karande H.A.: Toxicity studies on Nerium oleander leaf extract in male albino mice: an approach to develop oral contraceptive. J Herb Med Toxicol 2009, 3, 95–104. Narayane V.S. Pawakar A.P. Souza A.A. Karande H.A. Toxicity studies on Nerium oleander leaf extract in male albino mice: an approach to develop oral contraceptive J Herb Med Toxicol 2009 3 95 104 21 Ni D., Madden T.L., Johansen M., Felix E., Ho D.H., Newman R.A.: Murine pharmacokinetics and metabolism of oleandrin, a cytotoxic component of Nerium oleander

Open access
Research progress on anti-infection therapy for sepsis in children

, and other factors of the current, local, hospital, department, and use empirical antimicrobial agents early [ 24 ]. Moreover, whether the case is hospital-acquired or out-of-hospital infection should be determined, and the presence of a clear focus of infection should be known. The selected drug should be a wide spectrum of antimicrobial agent that covers possible pathogenic microorganisms (bacterial or fungal) and has good penetration in the likely infected tissue. The pharmacokinetics of the antimicrobials will change significantly during the course of treatment

Open access